Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 aug 2009 - 08:12
Statutaire naam
Crucell N.V.
Titel
Crucell Receives NIH Award for the Development of Influenza Monoclonal Antibodies
Bericht
Leiden, The Netherlands (August 18, 2009) – Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that it received a National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) contract aimed at advancing the development of monoclonal antibodies for the treatment of seasonal and pandemic influenza. The contract provides funding of up to $40.7 million, with additional options that may be triggered at the discretion of the NIH worth a further $28.4 million, bringing the potential total amount to $69.1 million.
“With the world now at pandemic alert level six, and recent reports of A/H1N1 oseltamivir resistance occurring, the timing of this contract is extremely important” said Dr. Jaap Goudsmit, Crucell's Chief Scientific Officer. “It will allow Crucell and its partners to pursue a new approach for the treatment of the disease caused by both seasonal and pandemic influenza strains.”
Datum laatste update: 01 september 2024